Calciumfolinat
Phase 2Small molecule
Calciumfolinat is one of 7 small molecule programs targeting Immune. It is currently in Phase 2.
1
Indications
2
Total Trials
1
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
6 competitors in Immune
#DrugCompanyPhaseTrials
1Tremfya
Johnson & JohnsonApproved
Tecentriq
RochePhase 2
Eloxatin
TevaPhase 2
Taxotere
AAvyxa
Phase 2
CM336
KKeymed Biosciences Co.Ltd
Phase 2
Calciumfolinat
IInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2
S-4321
SSeismic Therapeutic AU Pty Ltd
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Immune1 trial
Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness
Active, not recruiting·IInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest·Phase 2·NCT03421288·677 enrolled
Gastric1 trial
FLOT vs. FLOT/Ramucirumab for Perioperative Therapy of Gastric or GEJ Cancer (RAMSES)
Completed·IInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest·Phase 2/3·NCT02661971·180 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Calciumfolinat. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details